Zacks: Brokerages Anticipate Atara Biotherapeutics Inc (NASDAQ:ATRA) Will Announce Earnings of -$1.29 Per Share

Equities research analysts predict that Atara Biotherapeutics Inc (NASDAQ:ATRA) will report earnings per share (EPS) of ($1.29) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have provided estimates for Atara Biotherapeutics’ earnings, with the lowest EPS estimate coming in at ($1.32) and the highest estimate coming in at ($1.27). Atara Biotherapeutics posted earnings per share of ($1.75) during the same quarter last year, which suggests a positive year-over-year growth rate of 26.3%. The business is scheduled to announce its next earnings report on Tuesday, February 25th.

According to Zacks, analysts expect that Atara Biotherapeutics will report full year earnings of ($5.45) per share for the current fiscal year, with EPS estimates ranging from ($5.63) to ($5.14). For the next year, analysts expect that the business will report earnings of ($4.76) per share, with EPS estimates ranging from ($5.60) to ($3.09). Zacks Investment Research’s earnings per share calculations are an average based on a survey of analysts that cover Atara Biotherapeutics.

Atara Biotherapeutics (NASDAQ:ATRA) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($1.31) EPS for the quarter, beating analysts’ consensus estimates of ($1.40) by $0.09.

ATRA has been the subject of a number of recent research reports. JPMorgan Chase & Co. lowered Atara Biotherapeutics from an “overweight” rating to a “neutral” rating and cut their target price for the company from $43.00 to $22.00 in a research note on Friday, November 8th. ValuEngine upgraded Atara Biotherapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, October 2nd. Cowen restated a “buy” rating on shares of Atara Biotherapeutics in a research note on Tuesday, December 10th. Stifel Nicolaus restated a “buy” rating on shares of Atara Biotherapeutics in a research note on Friday, October 25th. Finally, Goldman Sachs Group lowered Atara Biotherapeutics from a “neutral” rating to a “sell” rating and cut their target price for the company from $14.00 to $9.00 in a research note on Friday, September 27th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating and eight have given a buy rating to the stock. The company currently has an average rating of “Hold” and a consensus price target of $28.22.

Hedge funds have recently made changes to their positions in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Atara Biotherapeutics by 59.8% during the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 2,699 shares of the biotechnology company’s stock valued at $38,000 after acquiring an additional 1,010 shares during the period. Tower Research Capital LLC TRC acquired a new position in shares of Atara Biotherapeutics during the third quarter valued at $40,000. Marshall Wace LLP acquired a new position in shares of Atara Biotherapeutics during the first quarter valued at $284,000. Bank of Montreal Can lifted its stake in shares of Atara Biotherapeutics by 81.1% during the second quarter. Bank of Montreal Can now owns 8,314 shares of the biotechnology company’s stock valued at $167,000 after acquiring an additional 3,723 shares during the period. Finally, Oppenheimer & Co. Inc. lifted its stake in shares of Atara Biotherapeutics by 25.2% during the third quarter. Oppenheimer & Co. Inc. now owns 12,682 shares of the biotechnology company’s stock valued at $179,000 after acquiring an additional 2,550 shares during the period.

Shares of NASDAQ ATRA traded down $0.96 during trading hours on Wednesday, reaching $15.03. The stock had a trading volume of 611,689 shares, compared to its average volume of 656,038. The business’s fifty day moving average is $15.64 and its two-hundred day moving average is $14.59. The company has a debt-to-equity ratio of 0.05, a current ratio of 9.56 and a quick ratio of 9.56. The company has a market cap of $813.88 million, a price-to-earnings ratio of -2.46 and a beta of 2.07. Atara Biotherapeutics has a twelve month low of $10.38 and a twelve month high of $41.97.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc, an off-the-shelf T-cell immunotherapy company, develops treatments for patients with cancer, autoimmune, and viral diseases in the United States. It is developing tabelecleucel, a T-cell immunotherapy that is Phase III clinical trials for the treatment of rituximab-refractory epstein-barr virus (EBV) associated post-transplant lymphoproliferative disorder, as well as other EBV associated hematologic and solid tumors, including nasopharyngeal carcinoma.

Further Reading: How much money do you need to begin day trading?

Get a free copy of the Zacks research report on Atara Biotherapeutics (ATRA)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Atara Biotherapeutics (NASDAQ:ATRA)

Receive News & Ratings for Atara Biotherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Atara Biotherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.